Dravet Syndrome Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dravet Syndrome pipeline constitutes 10+ key companies continuously working towards developing 12+ Dravet Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dravet Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dravet Syndrome Market.

The Dravet Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dravet Syndrome Pipeline Report: https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dravet Syndrome treatment therapies with a considerable amount of success over the years.
• Dravet Syndrome companies working in the treatment market are Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others, are developing therapies for the Dravet Syndrome treatment
• Emerging Dravet Syndrome therapies in the different phases of clinical trials are- TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others are expected to have a significant impact on the Dravet Syndrome market in the coming years.
• In July 2025, Stoke Therapeutics and Biogen recently shared new findings from several studies during a scientific conference.
• In February 2025, Biogen and Stoke Therapeutics formed a collaboration to jointly develop and commercialize zorevunersen as a potential treatment for Dravet syndrome.
• In January 2025, After the June 2024 announcement revealing that the Phase III SKYLINE (Dravet syndrome) and SKYWAY (Lennox-Gastaut syndrome) trials of soticlestat did not meet their primary endpoints, Takeda discontinued its development for LGS. Subsequently, the FDA indicated that the existing data were inadequate to support a New Drug Application (NDA) for Dravet syndrome.
• In January 2025, Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on restoring protein expression through RNA-based medicine, has reached an agreement with global regulatory agencies on the design of its Phase 3 EMPEROR study. This trial aims to evaluate zorevunersen as a potential first disease-modifying treatment for Dravet syndrome.
• In January 2025, The FDA awarded rare pediatric disease designation to relutrigine, a therapy developed by Praxis Precision Medicines for Dravet syndrome. This treatment is designed to help reduce seizures in children with epileptic disorders such as Dravet syndrome.
• In December 2024, Stoke Therapeutics, Inc. announced that the FDA has granted Breakthrough Therapy Designation to zorevunersen for treating Dravet syndrome in patients with a confirmed SCN1A gene mutation that is not linked to gain-of-function.

Dravet Syndrome Overview
Dravet Syndrome is a rare and severe form of epilepsy that typically begins in infancy, usually within the first year of life. It is characterized by prolonged, frequent, and treatment-resistant seizures, often triggered by fever or high temperatures. The condition is commonly caused by mutations in the SCN1A gene, which affects the brain's electrical signaling. Over time, individuals with Dravet Syndrome may experience developmental delays, speech and movement difficulties, and behavioral challenges. Due to its complex nature, treatment focuses on reducing seizure frequency using anti-seizure medications, dietary therapy, and emerging targeted therapies to improve quality of life.

Get a Free Sample PDF Report to know more about Dravet Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dravet Syndrome Drugs Under Different Phases of Clinical Development Include:
• TAK-935 (soticlestat): Takeda
• BELVIQ (lorcaserin): Eisai
• STK-001: Stoke Therapeurtics
• EPX-100: EpyGenix Therapeutics
• ganaxolone: Marinus Pharmaceuticals
• EPX-100 (Clemizole HCl): Epygenix
• STK-001: Stoke Therapeutics, Inc
• ZX008 (Fenfluramine Hydrochloride): Zogenix International Ltd, Inc.
• Soticlestat: Takeda
• GWP42003-P: Jazz Pharmaceuticals
• Soticlestat: Ovid Therapeutics Inc.
• LP352: Longboard Pharmaceuticals

Dravet Syndrome Route of Administration
Dravet Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Dravet Syndrome Molecule Type
Dravet Syndrome Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Dravet Syndrome Pipeline Therapeutics Assessment
• Dravet Syndrome Assessment by Product Type
• Dravet Syndrome By Stage and Product Type
• Dravet Syndrome Assessment by Route of Administration
• Dravet Syndrome By Stage and Route of Administration
• Dravet Syndrome Assessment by Molecule Type
• Dravet Syndrome by Stage and Molecule Type

DelveInsight's Dravet Syndrome Report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dravet Syndrome product details are provided in the report. Download the Dravet Syndrome pipeline report to learn more about the emerging Dravet Syndrome therapies
https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dravet Syndrome Therapeutics Market include:
Key companies developing therapies for Dravet Syndrome are - GW Pharmaceuticals, Biocodex, Zogenix, Stoke Therapeutics, Eisai Inc., Takeda, Epygenix Therapeutics, and Others.

Dravet Syndrome Pipeline Analysis:
The Dravet Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dravet Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dravet Syndrome Treatment.
• Dravet Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dravet Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dravet Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dravet Syndrome drugs and therapies
https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dravet Syndrome Pipeline Market Drivers
• The researchers are undergoing advancement in already approved drugs by providing an alternative means of delivering the drug.
• A broader awareness among health care providers and the public for better treatments helps to improve care and outcomes.
• Development of long-acting injectable Antipsychotics.

Dravet Syndrome Pipeline Market Barriers
• Demands of advanced therapeutics and presence of significant number of pipeline drugs.
• There is growing evidence that patients with a dual diagnosis does not respond well to conventional psychiatric treatment, creating demand for a new approach from a different perspective.
• Because of the increase in the side effects and less efficacious drug, the demand for specific therapy also increases.

Scope of Dravet Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others
• Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others
• Dravet Syndrome Therapeutic Assessment: Dravet Syndrome current marketed and Dravet Syndrome emerging therapies
• Dravet Syndrome Market Dynamics: Dravet Syndrome market drivers and Dravet Syndrome market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.